Compare NBHC & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBHC | DRTS |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2011 | 2021 |
| Metric | NBHC | DRTS |
|---|---|---|
| Price | $37.02 | $13.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $43.25 | $20.60 |
| AVG Volume (30 Days) | 386.6K | ★ 494.1K |
| Earning Date | 10-27-2026 | 11-23-2026 |
| Dividend Yield | ★ 3.44% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.84 | N/A |
| Revenue | ★ $47,100,000.00 | N/A |
| Revenue This Year | $23.56 | N/A |
| Revenue Next Year | $7.17 | $1,793.58 |
| P/E Ratio | $44.25 | ★ N/A |
| Revenue Growth | ★ 2.86 | N/A |
| 52 Week Low | $35.50 | $3.43 |
| 52 Week High | $47.28 | $15.79 |
| Indicator | NBHC | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 40.42 | 47.79 |
| Support Level | N/A | $12.33 |
| Resistance Level | $39.28 | $13.95 |
| Average True Range (ATR) | 0.88 | 0.66 |
| MACD | -0.00 | 0.10 |
| Stochastic Oscillator | 25.08 | 39.06 |
National Bank Holdings Corp offers a full range of banking products and financial services to commercial, business, and consumer clients predominantly in Colorado, with a focus on personalized service through relationship managers and banking center associates. The company provides commercial and industrial loans, non-owner occupied commercial real estate loans, Small Business Administration loans as a Preferred Lender Provider, U.S. Department of Agriculture and Farm Service Agency loans, commercial deposit and treasury management products, business online and mobile banking, consumer and residential real estate loans, deposit services, and trust and wealth management services. Its services emphasize full-relationship banking, integrating lending, deposits, and cash management solutions.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.